Sandoz US launches generic paclitaxel in single-dose vial, further expanding US oncology portfolioGlobeNewsWire • 10/11/24
Sandoz Canada achieves carbon neutral certification for its commercial operationsGlobeNewsWire • 10/07/24
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar positionGlobeNewsWire • 08/12/24
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseasesGlobeNewsWire • 07/25/24
FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in USGlobeNewsWire • 07/01/24
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in EuropeGlobeNewsWire • 05/22/24
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AGGlobeNewsWire • 04/30/24
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilarsGlobeNewsWire • 04/30/24
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offeringGlobeNewsWire • 04/22/24
Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicinesGlobeNewsWire • 03/21/24
Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US marketGlobeNewsWire • 03/04/24